Prevalence of Side Effects with Finasteride 1mg
Sexual side effects occur in approximately 2-4% more men taking finasteride 1mg compared to placebo, with the most common being decreased libido, erectile dysfunction, decreased ejaculate volume, and gynecomastia. 1
Sexual Dysfunction Rates
The guideline evidence from large-scale RCTs demonstrates that finasteride causes a 2-4% absolute increase in sexual adverse events above placebo rates 1. Specifically:
- Erectile dysfunction/impotence: Increased by 2-4% above placebo
- Decreased libido: Increased by 2-4% above placebo
- Decreased ejaculate volume: Increased by 2-4% above placebo
- Gynecomastia: Increased by 2-4% above placebo
Important context: The magnitude of sexual dysfunction is clinically modest. On a 0-100 scale measuring sexual function, finasteride caused a mean difference of only 3.21 points compared to 1.26 points for each additional year of age 1. This means the effect is smaller than natural age-related variability.
Temporal Pattern of Side Effects
Sexual dysfunction associated with finasteride decreases over time, though it remains statistically significant 1. New reports of drug-related sexual adverse experiences decreased with duration of therapy 2.
Overall Discontinuation Rates
The combined discontinuation rate specifically due to adverse events was approximately 6-7% for both finasteride and placebo groups 1. This indicates that while side effects occur more frequently with finasteride, they rarely lead to treatment discontinuation beyond baseline rates.
Dose-Specific Data for 1mg
While most guideline data comes from 5mg studies for BPH, a single study confirmed that 1mg finasteride (the hair loss dose) produces similar PSA suppression effects as 5mg in men age 50 and older 1. The FDA label confirms these side effects apply to the 1mg dose used for male pattern baldness 2.
Postmarketing Safety Signals
The FDA label notes rare postmarketing reports of 2:
- Persistent sexual dysfunction after discontinuation (frequency unknown from voluntary reporting)
- Depression
- Testicular pain
- Male infertility/poor seminal quality (reversible upon discontinuation)
Critical caveat: A 2025 pharmacovigilance study found emerging safety signals for suicidality, particularly in young males using finasteride for hair loss, with peaks in 2022-2024 3. While causality remains uncertain, this warrants mental health screening before and during treatment.
Clinical Implications for 1mg Use
For otherwise healthy men taking finasteride 1mg for hair loss:
- Expect sexual side effects in roughly 1 in 25-50 men (2-4% absolute increase)
- Most side effects are mild and may resolve with continued use
- The effect size is smaller than normal aging effects on sexual function
- Discontinuation rates due to side effects are similar to placebo
- Screen for depression/suicidality, especially in younger patients
- Counsel that rare cases of persistent dysfunction have been reported
The evidence demonstrates finasteride 1mg has a generally favorable safety profile with low absolute rates of side effects, though the small increased risk of sexual dysfunction and emerging psychiatric concerns require informed consent and monitoring.